Optical molecular imaging can differentiate metastatic from benign lymph nodes in head and neck cancer.
Nat Commun
; 10(1): 5044, 2019 11 06.
Article
em En
| MEDLINE
| ID: mdl-31695030
Identification of lymph node (LN) metastasis is essential for staging of solid tumors, and as a result, surgeons focus on harvesting significant numbers of LNs during ablative procedures for pathological evaluation. Isolating those LNs most likely to harbor metastatic disease can allow for a more rigorous evaluation of fewer LNs. Here we evaluate the impact of a systemically injected, near-infrared fluorescently-labeled, tumor-targeting contrast agent, panitumumab-IRDye800CW, to facilitate the identification of metastatic LNs in the ex vivo setting for head and neck cancer patients. Molecular imaging demonstrates a significantly higher mean fluorescence signal in metastatic LNs compared to benign LNs in head and neck cancer patients undergoing an elective neck dissection. Molecular imaging to preselect at-risk LNs may thus allow a more rigorous examination of LNs and subsequently lead to improved prognostication than regular neck dissection.
Texto completo:
1
Base de dados:
MEDLINE
Assunto principal:
Imagem Molecular
/
Imagem Óptica
/
Neoplasias de Cabeça e Pescoço
/
Linfonodos
/
Metástase Linfática
Limite:
Adult
/
Aged
/
Aged80
/
Female
/
Humans
/
Male
/
Middle aged
Idioma:
En
Ano de publicação:
2019
Tipo de documento:
Article